Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 20Carcinoma, Non-Small-Cell Lung 18Neoplasms 10Adenocarcinoma 8Neoplasm Metastasis 7Colorectal Neoplasms 7Carcinoma, Hepatocellular 6Esophageal Neoplasms 5Carcinoma, Renal Cell 5Breast Neoplasms 5Colonic Neoplasms 4Urinary Bladder Neoplasms 3Urethral Neoplasms 3Melanoma 3Liver Neoplasms 3Biliary Tract Neoplasms 3Ureteral Neoplasms 2Solid Tumors 2Sarcoma 2Rectal Neoplasms 2Ovarian Neoplasms 2Non-small Cell Lung Cancer Metastatic 2Malignant Solid Tumor 2Lung Neoplasms 2Fallopian Tube Neoplasms 2Carcinoma, Transitional Cell 2Solid Tumor 1Solid Cancer 1Sarcoma, Synovial 1Sarcoma, Alveolar Soft Part 1

Interventions

Bevacizumab 9Oxaliplatin 7Irinotecan 6Fluorouracil 6Nivolumab 5Leucovorin 5Cetuximab 5Capecitabine 5pembrolizumab 4Sunitinib 4IFL protocol 4Drug Therapy 4Cisplatin 4encorafenib 3Pemetrexed 3Gemcitabine 3Folfox protocol 35,10-methylenetetrahydrofolic acid 3trebananib 2trastuzumab deruxtecan 2amminedichloro(2-methylpyridine)platinum(II) 2Ocoxin 2N-(2-fluoro-4-((2-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)carbonylaminopyridin-4-yl)oxy)phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide 2Levoleucovorin 2IDRX-42 2CGX1321 2130-nm albumin-bound paclitaxel 2zanidatamab 1ulixertinib 1tivozanib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Gastrointestinal Neoplasms × Ramucirumab × Clear all
NCT05980416 2025-11-14

Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2

Elevation Oncology

Phase 1 Terminated
88 enrolled 18 charts
Gastrointestinal

Adenocarcinoma, Digestive System Neoplasms, Gastrointestinal Neoplasms, Neoplasms, Neoplasms by Site, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡